Last reviewed 2026-05-13 · How we verify

Cervavac as three dose regimen

Cervavac is a therapeutic HPV vaccine that stimulates the immune system to target and eliminate cervical cancer cells expressing human papillomavirus antigens.

Cervavac is a therapeutic HPV vaccine that stimulates the immune system to target and eliminate cervical cancer cells expressing human papillomavirus antigens. Used for Cervical cancer (therapeutic indication), HPV-associated cervical intraepithelial neoplasia.

At a glance

Mechanism of action

Cervavac is designed to induce cellular and humoral immune responses against HPV-infected cells, particularly those expressing HPV16 and HPV18 antigens that are associated with cervical cancer development. As a therapeutic vaccine administered in a three-dose regimen, it aims to boost the body's own immune system to recognize and destroy existing HPV-positive lesions and cancer cells, rather than prevent initial infection like prophylactic HPV vaccines.

Approved indications

• Cervical cancer (therapeutic indication)
• HPV-associated cervical intraepithelial neoplasia

Common side effects

• Injection site reactions (pain, erythema, swelling)
• Fever
• Fatigue
• Myalgia

Key clinical trials

• Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Cervavac as three dose regimen CI brief — competitive landscape report
• Cervavac as three dose regimen updates RSS · CI watch RSS
• Serum Institute of India Pvt. Ltd. portfolio CI